Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYD-0124 in adults with myotonic dystrophy type 1
jRCT2051190069Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2019
- Modality
- Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, double-blind trial of MYD-0124 in myotonic dystrophy type 1 (DM1) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety. Started Nov 2019; status: completed.
02
Drugs
MYD-0124
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on jRCT2051190069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190069.